Supported by grants from the National Eye Institute (NEI) Clinical Scientist Development award National Institutes of Health/NEI 5K12 EY016333-08 (EL; Bethesda, MD, USA). The parent clinical study was funded by Hoffmann- La Roche Ltd. (Basel, Switzerland) through a research agreement with Duke University (Durham, NC, USA).
Disclosure: A.C. Thompson, None; U.F.O. Luhmann, Roche (E); S.S. Stinnett, None; L. Vajzovic, Alcon (F), Janssen (R), Knights Templar Eye Foundation (R), PDCs ENABLE (R), Roche (F), Second Sight (F), F. Hoffmann-La Roche Ltd (E); A. Horne, None; C.A. Toth, Alcon (R), P; S.W. Cousins, Alimera (C), Bausch&Lomb (C, F), PanOptica (C), Stealth (C, F), Therakine (C); E.M. Lad, Hoffman (F), Roche (F), Apellis (F), Janssen Research (C), Genentech (C)